Atara biotherapeutics, inc. reports inducement grants under nasdaq listing rule 5635(c)(4)

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 93,950 restricted stock units of atara's common stock to three newly hired employees.
ATRA Ratings Summary
ATRA Quant Ranking